Edition:
India

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

14.70USD
15 Nov 2019
Change (% chg)

$0.58 (+4.14%)
Prev Close
$14.11
Open
$14.26
Day's High
$14.87
Day's Low
$14.03
Volume
215,540
Avg. Vol
249,459
52-wk High
$22.82
52-wk Low
$11.00

Latest Key Developments (Source: Significant Developments)

Fate Therapeutics Posts Q3 Loss Per Share Of $0.40
Wednesday, 6 Nov 2019 

Nov 5 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q3 REVENUE $2.4 MILLION VERSUS $1.0 MILLION.Q3 REVENUE ESTIMATE $1.8 MILLION -- REFINITIV IBES DATA.QTRLY NET LOSS PER COMMON SHARE $0.40.Q3 EARNINGS PER SHARE VIEW $-0.38 -- REFINITIV IBES DATA.  Full Article

Fate Therapeutics Prices Underwritten Public Offering Of 8.6 Mln Shares At $17.50/Shr
Thursday, 12 Sep 2019 

Sept 12 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.FATE THERAPEUTICS - ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 8.6 MILLION SHARES OF COMMON STOCK AT PUBLIC OFFERING PRICE OF $17.50 PER SHARE.  Full Article

Fate Therapeutics Inc Posts Loss Per Share Of $0.36
Wednesday, 7 Aug 2019 

Aug 6 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q2 REVENUE $2.8 MILLION VERSUS $1.0 MILLION.Q2 REVENUE ESTIMATE $1.2 MILLION -- REFINITIV IBES DATA.QTRLY LOSS PER SHARE $0.36.Q2 EARNINGS PER SHARE VIEW $-0.33 -- REFINITIV IBES DATA.  Full Article

Fate Therapeutics Reports Qtrly Net Loss Per Common Share $0.30
Wednesday, 8 May 2019 

May 7 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q1 REVENUE $2.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $2.4 MILLION.FATE THERAPEUTICS - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31, 2019 WERE $183.0 MILLION, COMPARED TO $201.0 MILLION AS OF DECEMBER 31, 2018.QTRLY NET LOSS PER COMMON SHARE $0.30.  Full Article

Fate Therapeutics Reports Q3 Revenue of $1 Million
Friday, 2 Nov 2018 

Nov 1 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q3 REVENUE $1.0 MILLION.Q3 REVENUE VIEW $2.9 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY LOSS PER SHARE $0.31.  Full Article

Ono Pharmaceutical says collaboration with Fate Therapeutics for two iPSC-derived CAR-T Therapies for Cancers
Tuesday, 18 Sep 2018 

Sept 18(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it entered into a collaboration agreement with Fate Therapeutics Inc <<>>, for the joint development and commercialization of two off-the-shelf chimeric antigen receptor(CAR)-T cell product candidates for cancer.  Full Article

Fate Therapeutics Files For Mixed Shelf Of Up To $150 Million
Saturday, 5 May 2018 

May 4 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING.  Full Article

Fate Therapeutics Q4 Loss Per Share $0.29​
Tuesday, 6 Mar 2018 

March 5 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q4 REVENUE $1.0 MILLION.QTRLY ‍LOSS PER SHARE $0.29​.Q4 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.  Full Article

Fate Therapeutics Announces Pricing Of Public Offering Of Common Stock
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.53 MILLION COMMON SHARES PRICED AT $4.20PER SHARE.  Full Article